WO2001010427A3 - Use of anti-muscarinic agents for treating skin disorders - Google Patents

Use of anti-muscarinic agents for treating skin disorders Download PDF

Info

Publication number
WO2001010427A3
WO2001010427A3 PCT/GB2000/003032 GB0003032W WO0110427A3 WO 2001010427 A3 WO2001010427 A3 WO 2001010427A3 GB 0003032 W GB0003032 W GB 0003032W WO 0110427 A3 WO0110427 A3 WO 0110427A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin disorders
treating skin
muscarinic agents
muscarinic
agents
Prior art date
Application number
PCT/GB2000/003032
Other languages
French (fr)
Other versions
WO2001010427A2 (en
Inventor
Paula Collier
David Thomas Manallack
Robin Mark Bannister
Original Assignee
Arakis Ltd
Paula Collier
David Thomas Manallack
Robin Mark Bannister
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arakis Ltd, Paula Collier, David Thomas Manallack, Robin Mark Bannister filed Critical Arakis Ltd
Priority to AU63064/00A priority Critical patent/AU6306400A/en
Priority to EP00949799A priority patent/EP1202723A2/en
Priority to IL14789100A priority patent/IL147891A0/en
Priority to JP2001514947A priority patent/JP2003506405A/en
Priority to CA002378445A priority patent/CA2378445A1/en
Publication of WO2001010427A2 publication Critical patent/WO2001010427A2/en
Publication of WO2001010427A3 publication Critical patent/WO2001010427A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound having anti-muscarinic activity, a dipole moment greater than 4D and anti-proliferation activity of at least 50% at 10 νM, e.g. glycopyrrolate, is useful for the treatment of skin conditions such as psoriasis.
PCT/GB2000/003032 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders WO2001010427A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU63064/00A AU6306400A (en) 1999-08-09 2000-08-07 Topical use of anti-muscarinic agents
EP00949799A EP1202723A2 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders
IL14789100A IL147891A0 (en) 1999-08-09 2000-08-07 Topical use of anti-muscarnic agents
JP2001514947A JP2003506405A (en) 1999-08-09 2000-08-07 Topical use of antimuscarinics
CA002378445A CA2378445A1 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918760.1A GB9918760D0 (en) 1999-08-09 1999-08-09 Topical treatment
GB9918760.1 1999-08-09

Publications (2)

Publication Number Publication Date
WO2001010427A2 WO2001010427A2 (en) 2001-02-15
WO2001010427A3 true WO2001010427A3 (en) 2001-09-20

Family

ID=10858850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003032 WO2001010427A2 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders

Country Status (8)

Country Link
EP (1) EP1202723A2 (en)
JP (1) JP2003506405A (en)
AU (1) AU6306400A (en)
CA (1) CA2378445A1 (en)
GB (1) GB9918760D0 (en)
IL (1) IL147891A0 (en)
WO (1) WO2001010427A2 (en)
ZA (1) ZA200200795B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004402A1 (en) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Ester derivatives
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
DE102004016179A1 (en) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Compounds for the treatment of proliferative processes
WO2006054312A1 (en) * 2004-11-16 2006-05-26 Munisekhar Medasani Ammonium compounds for treating psoriasis and eczema
WO2007071313A2 (en) * 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0611240D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2009068876A1 (en) * 2007-11-30 2009-06-04 Summit Corporation Plc Compositions for the treatment of skin disorders
WO2009150408A2 (en) * 2008-06-13 2009-12-17 Summit Corporation Plc Topical antimuscarinic formulations
CN105026369A (en) 2013-02-28 2015-11-04 德米拉股份有限公司 Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP3288527B1 (en) 2015-04-28 2020-02-19 Unilever PLC, a company registered in England and Wales under company no. 41424 of N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same
CN107531655B (en) 2015-04-28 2021-03-12 荷兰联合利华有限公司 N-aralkylcarbonyl-piperazine and N-aralkylcarbonyl-homopiperazine compounds and personal care compositions containing the same
CN112730821B (en) * 2019-10-14 2024-04-09 泰州医药城国科化物生物医药科技有限公司 Method for analyzing long-acting property of receptor antagonist
CN110898227A (en) * 2019-11-04 2020-03-24 上海交通大学医学院附属瑞金医院卢湾分院 Combined medicine for treating psoriasis and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
WO1999059577A1 (en) * 1998-05-21 1999-11-25 El Khoury George F Topical application of muscarinic analgesic drugs such as neostigmine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
WO1998000119A2 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Pharma Kg Applications of active substances affecting the functions of non neuronal acetylcholine
WO1999059577A1 (en) * 1998-05-21 1999-11-25 El Khoury George F Topical application of muscarinic analgesic drugs such as neostigmine

Also Published As

Publication number Publication date
WO2001010427A2 (en) 2001-02-15
AU6306400A (en) 2001-03-05
IL147891A0 (en) 2002-08-14
JP2003506405A (en) 2003-02-18
ZA200200795B (en) 2003-03-26
GB9918760D0 (en) 1999-10-13
EP1202723A2 (en) 2002-05-08
CA2378445A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
WO2001010427A3 (en) Use of anti-muscarinic agents for treating skin disorders
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
AU5752194A (en) Benzimidazole compounds, their use and preparation
AU4621893A (en) Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
WO2001022953A3 (en) Use of retigabin for treating neuropathic pain
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
RU94041950A (en) Use of compounds of 3-arylhydroxypropylamine order for enuresis treatment
AU6143794A (en) Use of riluzole for treating aids-related neural disorders
AU6801694A (en) The treatment of small animals
AU1186601A (en) Use of plant extracts for treatment of acne and furuncle
CA2267309A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
HU9700060D0 (en) New compound, it's production and it's use as active component of a medicine
GB9323808D0 (en) Composition containing zinc for the treatment of skin disorders
US4931457B1 (en) Naphthylamino-and naphthyloxy-pyridineamin compounds useful as topical antiinflammatory agents for the treatment of skin disorders
HK1017684A1 (en) Novel substituted 4-(1h-benzimidazol-2-yl)(1,4)diazepanes useful for the treatment of allergic diseases
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU7854094A (en) Use of amiodarone for the treatment of heart failure
AU5699396A (en) Compositions for the treatment of skin conditions
CA2279943A1 (en) Treatment of skin disorders
AU2754997A (en) The treatment of plant diseases
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
IL125605A0 (en) Novel substituted n-methyl-n-(4(4-(1h-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
HK1043938A1 (en) Composition for the treatment of psoriasis
AU7254494A (en) 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000949799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/00795

Country of ref document: ZA

Ref document number: 147891

Country of ref document: IL

Ref document number: 200200795

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2378445

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001351

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 63064/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10048744

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000949799

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000949799

Country of ref document: EP